Cardiovascular Research in Australia

Drug News and Perspectives

Volumn 16, Issue 8, 2003, Pages 540-550

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communication   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 3 PHENACYL 4,5 DIMETHYLTHIAZOLIUM; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ARGININE; ATORVASTATIN; ATRASENTAN; BENZENE DERIVATIVE; BIGUANIDE DERIVATIVE; CANDESARTAN; CERIVASTATIN; CHLORTALIDONE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; METOPROLOL; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; PACLITAXEL; PERINDOPRIL; PRAVASTATIN; RAPAMYCIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTATION; ARTIFICIAL HEART; AUSTRALIA; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SOLUBILITY; DRUG TARGETING; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; REGULATORY MECHANISM; RESTENOSIS; RHABDOMYOLYSIS; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SINUS NODE; TREATMENT OUTCOME; WINE;

AUSTRALIA; CARDIOVASCULAR DISEASES; HUMANS; RESEARCH;

EID: 0344444688     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Ichihara, K. and Satoh, K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 2002, 359: 2195-8.
2. Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute myocardial syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001. 285: 1711-8.
3. Liem, A., van Boven, A.J., Withagen, A.P et al. Fluvastatin in acute myocardial infarction: Effects on early and late ischemia and events - The FLORIDA trial. Circulation 2000, 102: 2672-d (Abstr).
4. Satoh, K. and Ichihara, K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J Cardiovasc Pharmacol 2000, 35: 256-62
5. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-9.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment of Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288: 2998-3007.
7. Sever, P.S., Dahlof, B., Poulter, N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003, 361: 1149-58.
8. de Lorgeril, M., Renaud, S., Mamelle, N. et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994, 343: 1454-9.
9. de Lorgeril, M., Salen, P., Martin, J.L. et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. Circulation 1999, 99: 779-85.
10. de Lorgeril, M., Salen, P., Martin, J.-L. et al. Wine drinking and risks of cardiovascular complications after recent acute myocardial infarction. Circulation 2002, 106: 1465-9.
11. Siscovick, D.S., Lemaitre, R.N. and Mozaffarian, D. The Fish Story-A diet-heart hypothesis with clinical implications: n-3 polyunsaturated fatty acids, myocardial vulnerability, and sudden death. Circulation 2003, 107: 2632-4.
12. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet 1999, 354: 447-55.
13. GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105: 1897-903.
14. Van Der Meer, A.L., James, N.L., Edwards, G.A. et al. Initial in vivo experience of the VentrAssist implantable rotary blood pump in sheep. Artif Organs 2003, 27: 21-6.
15. James, N.L., van der Meer, A.L., Edwards, G.A. et al. Implantation of the VentrAssist implantable rotary blood pump in sheep. ASAIO J 2003, 48: 454-8.
16. Carey, R.M., Wang, Z.Q. and Siragy, H.M. Update: Role of the angiotensin type-2 (AT2) receptor in blood pressure regulation. Curr Hypertens Rep 2000, 2: 198-201.
17. Abdalla, S., Lothers, H., Abdel-tawab. A.M. and Quitterer, U. The angiotensin H AT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001, 39721-6.
18. Barber, M.N., Sampey, D.B. and Widdop, R.E. AT2 receptor stimulation enhances antihypertensive effects of AT1 receptor antagonist in hypertensive rats. Hypertension 1999, 34: 1112-6.
19. Widdop, R.E., Matrougui, K., Levy, B.I. and Henrion, D. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 2002, 40: 516-20.
20. Carey, R.M. and Siragy, H.M. Newly recognized components of the renin-angiotensin system: Potential roles in cardiovascular and renal regulation. Endocr Rev 2003, 24: 261-71.
21. Chin-Dusting, J.P., Rasaratnam, B., Jennings, G.L. and Dudley, F.J. Effects of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med 1997, 127: 985-8.
22. Rasaratnam, B., Kaye, D., Jennings, G., Dudley, F. and Chin-Dusting, J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003, 139: 186-93.
23. Hattori, Y., Kasa, K. and Gross, S.S. Cationic amino acid transporter gene expression in cultured vascular smooth muscles cells and in rats. Am J Physiol 1999, 276: H2020-8.
24. Helmy, A., Newby, D.E., Jalan, R., Hayes, P.C. and Webb, D.J. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut 2003, 52: 410-5.
25. Chen, H.-C., Bouchie, J.L., Perez, A.S. et al. Role of the angiotensin AT1 receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscler Thromb Vasc Biol 2000, 20: 2297-302.
26. Ward, M.R., Agrotis, A., Kanellakis, R., Hall, J., Jennings, G. and Bobik, A. Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulations, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol 2002, 22: 940-8.
27. Hool, L.C. and Arthur, P.G. Decreasing cellular hydrogen peroxide with catalase mimics the effects of hypoxia on the sensitivity of the L-type Ca2+ channel to beta-adrenergic stimulation in cardiac myocytes. Circ Res 2002, 91: 601-9.
28. Woodcock, E.A., Wang, B.H., Arthur, J.F. et al. Inositol polyphosphate 1-phosphatase is a novel antihypertrophic factor. J Biol Chem 2002, 277: 22734-42.
29. Headrick, J.P., Willems, L., Ashton, K.J. et al. Ischaemic tolerance in aged mouse myocardium: The role of adenosine and effects of A1 adenosine receptor overexpression. J Physiol 2003, 549: 823-33.
30. Karck, M., Tanaka, S., Bolling S.F. et al. Myocardial protection by ischemic preconditioning and delta-opioid receptor activation in the isolated working rat heart. J Thorac Cardiovasc Surg 2001, 122: 986-92.
31. Thomas, W.G., Brandenburger, Y., Autelitano, D.J. et al. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor Circ Res 2002, 90: 135-42.
32. Mazzolai, L., Pedrazzini, T., Nicould, F. et al. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000, 35: 985-91.
33. Laurent, S., Boutouyrie, P., Asmar, R. et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37: 1236-7.
34. Medley, T.L., Kingwell, B.A., Gatzka, C.D., Pillay, P. and Cole, T.J. Matrix metalloproteinase-3 genotype contributed to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003, 92: 1254-61.
35. Curl, C.L., Wendt, I.R., Canny B.J. and Kotsanas G. Effects of ovariectomy and 17beta-oestradiol on [Ca2+]i in female rat cardiac myocytes. Clin Exp Pharmacol Physiol 2003, 30: 489-94.
36. Gao, X. M., Agrotis, A., Autelitano, D.J. et al. Sex hormones and cardiomyopathic phenotype induced by cardiac beta 2-adrenergic receptor overexpression. Endocrinology 2003, 144: 4097-105.
37. Du, X.J., Samuel, C.S., Gao, X.M. et al. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: A gender-specific phenotype. Cardiovasc Res 2003, 395-404.
38. Candido, R., Forbes, J.M., Thomas, M.C. et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003, 92: 785-92.
39. Crackower, M.A., Sarao, R., Oudit, G.Y. et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417: 822-8.
40. Tikellis, C., Johnson, C.I., Forbes, J.M. et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003, 41: 392-7.
41. de Dios, S.T., Bruemmer, D., Dilley, R.D. et al. Inhibitory activity of clinical peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003, 27: 2548-50.
42. Collins, A.R., Meehan, W.P., Kintscher, U. et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and non-diabetic low density lipoprotein, receptor-deficient mice. Arteriorscler Thromb Vasc Biol 2001, 21: 365-71.
43. Rosenkranz, A.C., Woods, R.L., Dusting, G.J. and Ritchie, R.H. Antihypertrophic actions of the natriuretic peptides in adult cardiomyocytes: Importance of cyclic GMP. Cardiovasc Res 2003, 515-22.
44. Rosenkranz, A.C., Hood, S.G., Woods, R.L., Dusting, G.J. and Ritchie, R.H. B-Type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: Importance of cyclic GMP. Diabetes 2003, 2389-95.
45. Kingwell, B.A., Formosa, M., Muhlmann, M., Bradley, S.J. and McConnell, G.K. Nitric oxide synthase reduces glucose uptake during exercise in individuals with type 2 diabetes more than in control subjects. Diabetes 2002, 2572-80.